𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Trastuzumab + vinorelbine promising in HER2-overexpressing metastatic breast cancer

Book ID
120843728
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2008
Weight
133 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Trastuzumab plus vinorelbine or taxane c
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
✍ Harold J. Burstein; Aparna Keshaviah; Ari D. Baron; Ronald D. Hart; Rosemary Lam πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 157 KB

## Abstract ## BACKGROUND. The optimal trastuzumab‐based chemotherapy regimen for HER2‐overexpressing, metastatic breast cancer is not known. The __tr__astuzumab __a__nd __vi__norelbine __o__r __ta__xane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare